Thomas Ichim, Ph.D.

Chief Executive Officer

Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. Thomas Ichim hopes to greatly add to the value of Batu Biologics by leveraging his existing contacts and experience in product development, regulatory filings, and business development.

Gerry Berg

Chief Financial Officer

Mr. Berg has over 30 years of senior management experience working with private and public companies. Mr. Berg has served a number of public companies as their Chief Executive Officer, President, Chief Financial Officer or as a financial consultant. He has also served on the Board of Directors for a number of public companies. He has been responsible for manufacturing, inventory control, product procurement, and quality control departments. He has managed shareholder relations, financial reviews, budgeting, contract analysis, legal services and banking relationships. Mr. Berg began his career as a Certified Public Accountant with the firm of Deloitte & Touche (Deloitte). He served as Audit Manager for the Buick Motor Division of General Motors Corporation as one of his primary assignments. Mr. Berg holds a Bachelors of Arts in Accounting from Walsh College where he graduated Cum Laude. Mr. Berg became a Certified Public Accountant (CPA) in the State of Michigan in 1979 and in the State of California in 1984.

Alan J Lewis, Ph.D.

Founder, Chairman

Dr. Lewis is an industry veteran with over 37 years of experience as an executive in the life science industry. He spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice President of Research, leading translational research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. He later became the CEO of Signal Pharmaceuticals, a company focusing on small-molecule drug discovery and development, which was eventually acquired by Celgene in 2010. Subsequent to his employment as President of Celgene, Dr. Lewis had several successful business ventures, including raising $27 million as CEO of Novocell, becoming the CEO of the Juvenile Diabetes Research Foundation, and raising over $45 million as CEO of Ambit.

Thomas Ichim, Ph.D.

Founder and CEO

Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. Thomas Ichim hopes to greatly add to the value of Batu Biologics by leveraging his existing contacts and experience in product development, regulatory filings, and business development.

John Chiplin, Ph.D.

Board Member

John Chiplin, PhD, has significant international experience in the life science and technology industries, from both an operational and investment perspective. Recent transactions that Dr. Chiplin has been involved in include Medistem (acquired by Intrexon), Arana (acquired by Cephalon), and Domantis (acquired by GSK). Immediately prior to running Arana, Dr. Chiplin was head of the ITI Life Sciences investment fund in the UK. His own investment vehicle, Newstar Ventures Ltd, has funded more than twenty early stage companies in the past ten years. Dr. Chiplin’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. He currently serves on several international boards as a director or advisor. These span the public, private, venture capital and banking sectors.

Vladimir Bogin, MD, FACP

Board Member

Dr. Bogin started his medical training at Moscow Medical Academy, then trained at Yale and Brown Universities and received his postgraduate training at the University of Rochester where he was also elected to a chief medical resident position. Vlad has been involved in the drug development cycle for over 15 years, from basic discovery research to clinical trial design and multinational phase III and IV trials. As the director at Boehringer Ingelheim he was in charge of late stage development of a leading cardiology product. As the Chairman of the Board at Medistem Inc. Vlad was instrumental in its advancement from preclinical to clinical stage, from a non-reporting to a fully reporting publicly trading company and for subsequent successful liquidity event in 2014. Vlad is founder and CEO of Cromos Pharma, a clinical research organization that has conducted over a hundred clinical trials in Eastern Europe and in former Soviet republics. He maintains active medical license and hospital privileges in Washington and is an advisor to numerous companies and non-profit organizations. Vlad is an author of many peer-reviewed articles, book chapters and patents.

Samuel C Wagner

Founder and Board Member

Samuel Wagner is a founder of Batu Biologics and has served as its President and Chief Executive Officer since January of 2014. Wagner studied engineering at the University of California San Diego, and was a member of the esteemed engineering honor society, Tau Beta Pi. Following a successful series of investments in various ventures, Wagner took a dramatic change in his career path, seeking private investment and leadership opportunities in the biotech sector. Wagner hopes to help the lives of patients with devastating diseases by organizing and leading teams of highly qualified individuals to develop innovative therapeutics. Wagner hopes to utilize the success of this company and his future successes to drive his thirst for entrepreneurship, and to give back to the communities that helped foster his growth.

Hong Ma, MD, Ph.D., M.B.A.

Board Member

Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

John Peck, Jr.

Board Member

John Peck Jr graduated from Northern Illinois University in 1966 with a BS in Business. He spent the next three years in the US Army as an ordinance officer stationed in Southeast Asia. Upon returning to the States in 1969 he worked for RCA and Intel while pursuing an MBA at Depaul University. In 1976 John joined Meridian Leasing as employee number 5. In 1994 John (now CEO) and a Partner purchased Meridian Leasing (now 150 strong) from ownership that was in a consolidation mode. John’s share was bought out in 1997 and he started investing in commercial real estate with an emphasis on the large Multifamily properties. Currently John is doing a little land development work and has found the “New Wave of the Future”in the Biotech Community. At present he is invested in 7 Biotech firms. John and his wife,Vera, have been married for over 45 years and have had two children.

Gerry Berg

Board Member Chief Financial Officer

Mr. Berg has over 30 years of senior management experience working with private and public companies. Mr. Berg has served a number of public companies as their Chief Executive Officer, President, Chief Financial Officer or as a financial consultant. He has also served on the Board of Directors for a number of public companies. He has been responsible for manufacturing, inventory control, product procurement, and quality control departments. He has managed shareholder relations, financial reviews, budgeting, contract analysis, legal services and banking relationships. Mr. Berg began his career as a Certified Public Accountant with the firm of Deloitte & Touche (Deloitte). He served as Audit Manager for the Buick Motor Division of General Motors Corporation as one of his primary assignments. Mr. Berg holds a Bachelors of Arts in Accounting from Walsh College where he graduated Cum Laude. Mr. Berg became a Certified Public Accountant (CPA) in the State of Michigan in 1979 and in the State of California in 1984.

Yi Liang

Board Observer

Mr. Liang is an experienced Equity and venture investor with investment focus on new materials (Graphene, etc), and the development and application of high-tech energy technologies (hydrogen applications, hydrogen fuel cells, etc.). He currently holds executive positions in several companies including: Chairman of Dalian Lingfeng Investment, Chairman of Dalian Lingfeng Energy Co., and Chairman of Dalian Ai Mute Hydrogen Energy Co.

Dennis Van Epps, Ph.D.

Dennis Van Epps, Ph.D. is an experienced Research and Development Executive with over 25 years of industry experience in large corporations and small startup companies that have gone public. He obtained his Ph.D. in Microbiology and Immunology from the University of Illinois Medical Center in Chicago and went on to become a tenured Professor in the Departments of Medicine, Pathology and Microbiology at the University of New Mexico Medical School. He later joined Baxter Healthcare Corporation as a Director of Immunology in their Corporate Research Facility and became Vice President of Research for the Immunotherapy Division. He later joined CancerVax Corporation as Vice President of R&D and served as a Corporate Officer. He then joined Allergan as Vice President Research for the Medical Device Division focused on implantable and injectable aesthetic devices and served as Vice President of New Device Technology Assessment exploring new product opportunities prior to the acquisition of Allergan by Actavis in 2015. He has published over 140 scientific articles in immunology, cell therapy, neuroimmunology, stem cell technology and inflammation and has been an inventor on over 20 patents.

Deyu Fang, Ph.D.

Deyu is an immunologist and professor working in the Department of Pathology at Northwestern University Feinberg School of Medicine. Dr. Fang will provide Batu Biologics oversight in the development of ValloVax, assisting in the design and implementation of IND-enabling experiments. Dr. Fang has several lung cancer mouse models that can be used to quantify the anti-tumor activity of ValloVax™. Additionally, Dr. Fang has won several awards throughout his research career, including NIH Type 1 Diabetes Pathfinder Award and the AAI (American Association of Immunologist) Young Investigator Travel Award. Dr. Fang is a recipient of over 12 of NIH grants since 2009 to present. With the current active three of RO1 NIH, his research focuses on T cell activation, immune tolerance and autoimmunity.

John Peck, Jr.

John Peck Jr graduated from Northern Illinois University in 1966 with a BS in Business. He spent the next three years in the US Army as an ordinance officer stationed in Southeast Asia. Upon returning to the States in 1969 he worked for RCA and Intel while pursuing an MBA at Depaul University. In 1976 John joined Meridian Leasing as employee number 5. In 1994 John (now CEO) and a Partner purchased Meridian Leasing (now 150 strong) from ownership that was in a consolidation mode. John’s share was bought out in 1997 and he started investing in commercial real estate with an emphasis on the large Multifamily properties. Currently John is doing a little land development work and has found the “New Wave of the Future”in the Biotech Community. At present he is invested in 7 Biotech firms. John and his wife,Vera, have been married for over 45 years and have had two children.

Paulo Ferraz

Mr. Ferraz has pioneered the introduction of Information Technology in a variety of fields and markets around the world for four decades. In the eighties he developed multiple technical systems working as a systems analyst for Control Data Corporation in Brazil, including military and space applications using Artificial Intelligence. In the early nineties Paulo moved his interests and skills to biotech and the nascent internet industry, helping to open new markets in molecular modeling and drug discovery as Latin America Operations Director for San Diego-based Biosym Technologies. Paulo co-founded and was the CEO of biotech and IT companies like Biobras Software and Steps Technologies, setting up disruptive projects like a web-based insulin dosage platform in collaboration with University of Miami and an award-winning Virtual Reality industrial training tool, as well the invention and deployment of the US first internet-based Learning Management System and development of educational software reaching millions of students in the US, Europe, and Asia. Paulo studied Electrical Engineering and Information Systems at UFMG – Minas Gerais Federal University in Brazil. Mr. Ferraz is currently BRICS/Emerging Markets Director at Newstar Ventures, an international investment fund headquartered in La Jolla.

Francesco Marincola, MD

Dr. Francesco M. Marincola is a Distinguished Research Fellow at AbbVie Biotherapeutics Corporation, in Redwood City, California. Previously, he was the Inaugural Chief Research Officer of Sidra Medical and Research Centre in Doha, Qatar. He was previously a tenured Senior Investigator at the U.S. National Institutes of Health. He is past-President of the Society for the Immunotherapy of Cancer and Editor-in-Chief of the Journal of Translational Medicine. He received his MD summa cum laude from the University of Milan and did his surgery training at Stanford University, California. His scientific work deepened the understanding of the mechanisms leading to rejection of tumours or transplanted organs by the immune system and development of autoimmunity. With over 600 peer-reviewed scientific papers, Dr. Marincola is considered one of the world’s leading experts in cancer immunotherapy.

Mai H. Le, MD

Mai is a strategic advisor for biotechnology companies with a focus in oncology and immunotherapy. Dr. Le has over 8 years of oncology drug development experience that includes small molecules, biologics, medical devices and companion diagnostics strategy. She previously served as a medical director at Calithera Biosciences, Plexxikon Inc., Onyx Pharmaceuticals and Proteolix, Inc (acquired by Onyx Pharmaceuticals), and most recently, as the Chief Medical Officer at OncoSec Medical, Inc. Dr. Le obtained a medical degree from the University of Rochester School of Medicine and Dentistry and trained in Laboratory Medicine at University of California, San Francisco.

Boris Minev, MD, Ph.D.

Boris is currently the Director of Immunotherapy and Translational Oncology at Genelux Corporation studying the phenotype and characterization of metastasized cancer cells circulation. Dr. Minev previously worked as the Principal Investigate at the Laboratory of Tumor Immunology and Immunotherapy at the Moores UCSD Cancer Center. Dr. Minev has an extensive experience with cancer vaccines, having worked closely on the development of the first tumor vaccine to be approved by a regulatory body (Melacine).